Experience

Hengrui Pharma and GSK Enter Agreement to Develop up to 12 Medicines

July 27, 2025

Cooley advised Hengrui Pharma, a global pharmaceutical company, on its up to $12.5 billion agreement with GSK to develop up to 12 medicines to complement GSKs extensive respiratory, immunology and inflammation (RI&I) and oncology pipeline.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Frances Stocks Allen
Partner, London
Jiqiang Lin
Associate, New York
Freddy Yip
Associate, Hong Kong
Aaron Pomeroy
Partner, Colorado
David Wilson
Partner, London
Dr. Xiaozhen (Shawn) Yu
Partner, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
David Burns
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Robert Eisenbach
Of Counsel, San Francisco
Navya Dasari
Associate, New York
Rick Jantz
Associate, Santa Monica
Eerik Kukebal
Associate, London
Daniel Millard
Associate, London
Patrick Sharma
Associate, Santa Monica
Zhijing Yu
Associate, Singapore

Related Practices & Industries

Somite AI Announces $47 Million Series A

June 11, 2025

Cooley advised Somite AI, a techbio company leveraging foundation models and proprietary artificial intelligence to accelerate human cell therapy development, on the close of its $47 million Series A.

Read more

Related contacts

Stephane Levy
Partner, New York
Andrew Gunther
Associate, New York
Liz Gold
Associate, New York
Caolinn Mejza
Associate, New York
Mika Reiner Mayer
Partner, Palo Alto
Alan W. Tamarelli
Partner, New York
Jonathan Rivinus
Partner, Colorado
Calvin Lee
Associate, New York
Kevin Gurley
Quantitative Analyst, New York

Related Practices & Industries

Sirius Therapeutics Announces Collaboration With CRISPR Therapeutics

May 19, 2025

Cooley advised Sirius Therapeutics, a clinical-stage biotech company developing innovative small interfering RNA (siRNA) therapies for global markets, on its strategic partnership to develop and commercialize siRNA therapies with CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Jiqiang Lin
Associate, New York
Navya Dasari
Associate, New York
Aaron Pomeroy
Partner, Colorado
Todd Gluth
Partner, San Diego
Rick Jantz
Associate, Santa Monica
Steve Przesmicki
Partner, San Diego
Robert Eisenbach
Of Counsel, San Francisco
Rachel Thorn
Of counsel, New York
David Burns
Special Counsel, Washington, DC
Eileen Marshall
Partner, Washington, DC
Jonathan Rivinus
Partner, Colorado

Related Practices & Industries

Hengrui Pharmaceuticals Announces License Agreement With Merck KGaA

April 8, 2025

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck KGaA, Darmstadt, Germany for the commercialization in mainland China of SHR7280, an oral small-molecule gonadotropin-releasing hormone receptor antagonist, for indications including medical-assisted reproduction and gynecology.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Freddy Yip
Associate, Hong Kong
Caroline Vu
Special Counsel, Palo Alto
Letian Wei
Legal Consultant, Shanghai
Marc Suskin
Partner, New York
Sharon Connaughton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Rebecca Ross
Special Counsel, Washington, DC
Bin Wang
Special Counsel, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Natasha Leskovsek
Of Counsel, Washington, DC
Jiqiang Lin
Associate, New York
Amanda Pacheco
Associate, Palo Alto

Related Practices & Industries

Jiangsu Hengrui Pharmaceuticals Announces License Agreement With Merck

March 25, 2025

Cooley advised Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma), a global pharmaceutical company focused on scientific and technological innovation, on its exclusive license agreement with Merck (NYSE: MRK), known as MSD outside of the US and Canada, for HRS-5346, an investigational oral small molecule lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a phase 2 clinical trial in China.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Jiqiang Lin
Associate, New York
Andrew Epstein
Special Counsel, Seattle
Zhijing Yu
Associate, Singapore
David Burns
Special Counsel, Washington, DC
Julia R. Brinton
Special Counsel, Washington, DC
Navya Dasari
Associate, New York
Amanda Pacheco
Associate, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Russell Anderson
Partner, London
Megan Browdie
Partner, Washington, DC
Steve Przesmicki
Partner, San Diego

Related Practices & Industries

View more

Admissions and credentials

Massachusetts

New York

Pennsylvania

Rankings and accolades

Legal 500 US: Recommended for Commercial Deals and Contracts (2018)

Legal 500 US: Recommended for Technology Transactions (2018)